CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Future investigations will involve the utilization of macrophages derived from induced pluripotent stem cells (iPSCs) and the isolation of CD34+ stem cells from CML patients to validate the targeted phagocytic effects of CAR-M.